自体外周血造血干细胞移植与硼替佐米联合地塞米松治疗原发性轻链型淀粉样变性的疗效和安全性比较
目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官...
Saved in:
Published in | 中华血液学杂志 Vol. 37; no. 4; pp. 283 - 287 |
---|---|
Main Author | |
Format | Journal Article |
Language | Chinese |
Published |
210002,南京军区南京总医院血液科
2016
|
Subjects | |
Online Access | Get full text |
ISSN | 0253-2727 |
DOI | 10.3760/cma.j.issn.0253-2727.2016.04.007 |
Cover
Abstract | 目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032]。两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683)。auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P〈0.001)、发热(P〈0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P〉0.05)。结论auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见。 |
---|---|
AbstractList | 目的比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性。方法回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例。结果所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月。38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032]。两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683)。auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P〈0.001)、发热(P〈0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P〉0.05)。结论auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见。 目的 比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性.方法 回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例.结果 所有患者的中位随访时间为34(1~112)个月,auto-PBSCT组为38(5~112)个月,VD组为31(1~108)个月.38例患者中15例(39.5%)获得器官缓解,auto-PBSCT组和VD组器官缓解率差异无统计学意义[33.3%(5/15)对43.5%(10/23),P=0.532],达到器官缓解的中位时间差异有统计学意义[6(3~10)个月对3(1~6)个月,P=0.032].两组患者的3年总生存率分别为72.0%和66.9%,预期总生存期分别为84.7个月和75.9个月(P=0.683).auto-PBSCT组Ⅲ/Ⅳ级骨髓抑制(P<0.001)、发热(P<0.001)和恶心、呕吐(P=0.006)的发生率高于VD组,而肺感染(P=0.069)、血流感染(P=0.059)的发生率差异无统计学意义(P>0.05).结论 auto-PBSCT和VD方案治疗原发性轻链型淀粉样变性患者的器官缓解率相当,生存时间无明显差异,但auto-PBSCT组不良反应更多见. |
Abstract_FL | Objective To explore the feature of primary light chain amyloidosis patients treated with high-dose melphalan with auto peripheral blood stem cell transplantation (auto-PBSCT) and bortezomib plus dexamethasone (VD).Methods Thirty-eight patients diagnosed from September 2004 to September 2012 were analyzed retrospectively,including 15 cases received auto-PBSCT,23 cases exposed with VD.Results The median follow-up duration for the patients was 34 months (range,l-112 months),including auto-PBSCT group of 38 months (range,5-112 months) and VD group of 31 months (range,1-108 months).The organ response rate in all the patients was 39.5% (15/38),and the organ response rate between these two groups has no significant difference [33.3%(5/15) vs 43.5% (10/23),P=0.532].However,the median time of organ response was significant difference [6 (3-10) months vs 3 (1-6) months,respectively (P=0.032)].The 3-year overall survival (OS) rates in the two groups were 72.0% and 66.9%,and their average survival were 84.7 months and 75.9 months,respectively (P=0.683).In the patients with auto-PBSCT,the occurrence of Ⅲ-Ⅳ grade of bone marrow suppression (P < 0.001),fever (P < 0.001),nausea and infection (P=0.006) were obviously higher than those with VD,but there was no statistically significant difference in pulmonary infection (P=0.069) and bloodstream infection (P=0.059).Conclusions The preliminary results have presented that primary light chain amyloidosis patients treated with auto-PBSCT or VD had similar organ response rate and survival.However,more adverse events occurred in the group of auto-PBSCT. |
Author | 赵茜 王利平 宋萍 李锋 周小钢 于亚平 安志明 王旭丽 翟勇平 |
AuthorAffiliation | 南京军区南京总医院血液科,210002 |
AuthorAffiliation_xml | – name: 210002,南京军区南京总医院血液科 |
Author_xml | – sequence: 1 fullname: 赵茜 王利平 宋萍 李锋 周小钢 于亚平 安志明 王旭丽 翟勇平 |
BookMark | eNo9kMlKA0EQhvug4PoSHsTLjD3Tne7JUYIbCF5yD51JjyboRDOIyyniEoOaqIkLLtGAoHhwiYcoMfFl0j3jW9iieKmivvqogr8HdLhplwMwZEAdUQKH7Xmmp_Sk57k6NENIM6lJdRMaRIdYh5B2gO5_3gV6PC8FIVZ73A1yQe6h3SyJ2xNxeB9Us1_ZG1XFe81vbAcbFf-uIW_3228Fv_ohLz7bzQP_5TVYL4uDHXH5LKoVNcqrlqw1_JNTUbgWxUOZvQuaja9SS1R2ZT3r1_Lypi6KZ4r755tKk8c74mhPPObF1r2C8qkctDb6QKfD5jze_9d7QXRsNBqZ0KamxycjI1OaHbKoxk0HUYeQsOEgHo4jJ4EZw5RgzBKc2QkjbpmEG4SGOLQwpWEecsIcc2jzeNxACPWCwd-zy8x1mDsTS6WXMq56GFubXVld-ckMYpWYEgd-RXs27c4sJpW6kEnOs8xqjBALWyaiCH0Dffyk4w |
ContentType | Journal Article |
Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
DOI | 10.3760/cma.j.issn.0253-2727.2016.04.007 |
DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 维普中文期刊数据库 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone |
DocumentTitle_FL | Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone |
EndPage | 287 |
ExternalDocumentID | zhxyx201604007 668482373 |
GrantInformation_xml | – fundername: 南京军区医学科技创新项目(10MA096) Medical Science and Technology Innovation Project of Nanjing Military Region funderid: (10MA096) |
GroupedDBID | --- -05 2B. 2C~ 2RA 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 F5P OK1 RPM TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX |
ID | FETCH-LOGICAL-c587-e2f37f6691f3e9b3fd4aa47644adeacd1b826e1675e084779e5f9e4e0cebb1333 |
ISSN | 0253-2727 |
IngestDate | Thu May 29 04:03:11 EDT 2025 Wed Feb 14 10:20:12 EST 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 4 |
Keywords | Immunoglobulin light chains Retrospective studies Bortezomib 硼替佐米 免疫球蛋白轻链 Amyloidosis 淀粉样变性 造血干细胞移植 回顾性研究 Hematopoietic stem cell transplantation |
Language | Chinese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c587-e2f37f6691f3e9b3fd4aa47644adeacd1b826e1675e084779e5f9e4e0cebb1333 |
Notes | Amyloidosis; Immunoglobulin light chains; Hematopoietic stem cell transplantation; Retrospective studies; Bortezomib Zhao Qian, Wang Liping, Song Ping, Li Feng, Zhou Xiaogang, Yu Yaping, An Zhiming, Wang Xuli, Zhai Yongping.( Department of Hematology, Jinling Hospital, Nanjing 210002, China ) Objective To explore the feature of primary light chain amyloidosis patients treated with high-dose melphalan with auto peripheral blood stem cell transplantation (auto-PBSCT) and bortezomib plus dexamethasone (VD). Methods Thirty-eight patients diagnosed from September 2004 to September 2012 were analyzed retrospectively, including 15 cases received auto-PBSCT, 23 cases exposed with VD. Results The median follow-up duration for the patients was 34 months (range, 1-112 months), including auto-PBSCT group of 38 months (range, 5-112 months) and VD group of 31 months (range, 1-108 months). The organ response rate in all the patients was 39.5% (15/38), and the organ response rate between these two groups has no significant dif |
PageCount | 5 |
ParticipantIDs | wanfang_journals_zhxyx201604007 chongqing_primary_668482373 |
PublicationCentury | 2000 |
PublicationDate | 2016 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – year: 2016 text: 2016 |
PublicationDecade | 2010 |
PublicationTitle | 中华血液学杂志 |
PublicationTitleAlternate | Chinese Journal of Hematology |
PublicationTitle_FL | Chinese Journal of Hematology |
PublicationYear | 2016 |
Publisher | 210002,南京军区南京总医院血液科 |
Publisher_xml | – name: 210002,南京军区南京总医院血液科 |
SSID | ssj0042014 ssib051368330 ssib017477332 ssib001103535 ssib058574913 |
Score | 2.054595 |
Snippet | ... 目的 比较大剂量马法兰预处理的自体外周血造血干细胞移植(auto-PBSCT)与硼替佐米联合地塞米松(VD方案)治疗原发性轻链型淀粉样变性的疗效和安全性.方法 回顾性分析2004年9月至2012年9月38例原发性轻链型淀粉样变性患者的临床资料,其中auto-PBSCT组15例,VD组23例.结果... |
SourceID | wanfang chongqing |
SourceType | Aggregation Database Publisher |
StartPage | 283 |
SubjectTerms | 免疫球蛋白轻链 回顾性研究 淀粉样变性 硼替佐米 造血干细胞移植 |
Title | 自体外周血造血干细胞移植与硼替佐米联合地塞米松治疗原发性轻链型淀粉样变性的疗效和安全性比较 |
URI | http://lib.cqvip.com/qk/93752X/201604/668482373.html https://d.wanfangdata.com.cn/periodical/zhxyx201604007 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JaxRBFG40gngRRUWNSw4WCMPEXms5ds_0IB48RcgtdM_0GAQnLhE0p0jUJLhrXHCJCQiKB5d4UImJfybdM_4L33u92Ki4wVBUv3r1va2661VTXaNpByKuZGC1o6ohQ70Kd6JRDbloVZtK6q12SzoqoF2-R_nhY_aRYWd4XZ9f2rV0bjwcbE788ruS_4kq0CCu-JXsP0S2AAUC1CG-UEKEofyrGDNfMljMuy7zbebVmbKY7zDXZopjRRnMlcjjGrihwVdYunqJ4jBPMc9kvmCexyQnQIspHykuEX2OgLJOIqA1bTKYV8Mm5TGvkUvXCQeaLMIxmLJJDZ1JSZUa80godE9FZMyAU2eejxVQBoUKNEEJZAaJqkGVBloEPGiFQBEgFJkVGo7dHYSVpLMnyECBgFKRFToSMxxZwgFZLpN2SSiUTq4zdK-Rzj7hAN0hrxbdAblBlkrUIf2_nDzdz5zm1qljnbxXOB-UJHsRvM5cnvlBEgW8qooUgbAd_KFfa-DICmorU2NJVVfl0bQquboesqP365Uc2ydvQTy9SmmEOBgXcAu2mcw1K6S3S-xUAQf9hK4KNQkch0ZZK_Kkmw8br05tyJ7G0sOBm2OWXz2l38Rmc5PpWFVTpMc65BNpenpP9sCwy7Ni5vsouxK_mrtxdxbccM2TweAJEjJYCMEdmHwwPef-e95S7CblXNp45pK1XttgCmE4P7y0gwzXcr6vCmANLkTp1D7HsLikPdZpAmeDNDp1Lhe_UTuY6XfoT9rhCS2jY53jpyHvpM8AO-2gc7yUsQ5t0TZnS80BN31ubNXWTYxu06Z706_WVu7Gz-_Ht1_2Fie_Ti5AGX9a6i5f6U3Nd18sJ8-vr3280V38nDz-srZyq_vufe_iXHxrJn7yNl6ch8vk6WqytNy9_yC-8Sy-eTuZfNFbWf56dzWev5p8mOwuzSYLH-KbD4HefXQJ2JJ7M_Gda_Hr2fjySyAmb-Z6q1PbtaGGP1Q7XM3-jKXadCAPicy2JdqcK6NtRSq02i07CGwBq6mgBblbywilySODCyfSIeEVKnLaKrIjvRmFoWFZ1g6trzPWiXZqA01wHNejUPAwtGFBqoTZagWw8ItsoxmEfJfWX_hw5FR65s5IEeNd2v7MqyPZk_jsyMTo-QvnMQqYkYjdv-3fr21CzvQt6h6tb_zMuWgvrCvGw300ar4BEhHwIQ |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%87%AA%E4%BD%93%E5%A4%96%E5%91%A8%E8%A1%80%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E4%B8%8E%E7%A1%BC%E6%9B%BF%E4%BD%90%E7%B1%B3%E8%81%94%E5%90%88%E5%9C%B0%E5%A1%9E%E7%B1%B3%E6%9D%BE%E6%B2%BB%E7%96%97%E5%8E%9F%E5%8F%91%E6%80%A7%E8%BD%BB%E9%93%BE%E5%9E%8B%E6%B7%80%E7%B2%89%E6%A0%B7%E5%8F%98%E6%80%A7%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E5%AE%89%E5%85%A8%E6%80%A7%E6%AF%94%E8%BE%83&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E8%B5%B5%E8%8C%9C+%E7%8E%8B%E5%88%A9%E5%B9%B3+%E5%AE%8B%E8%90%8D+%E6%9D%8E%E9%94%8B+%E5%91%A8%E5%B0%8F%E9%92%A2+%E4%BA%8E%E4%BA%9A%E5%B9%B3+%E5%AE%89%E5%BF%97%E6%98%8E+%E7%8E%8B%E6%97%AD%E4%B8%BD+%E7%BF%9F%E5%8B%87%E5%B9%B3&rft.date=2016&rft.issn=0253-2727&rft.volume=37&rft.issue=4&rft.spage=283&rft.epage=287&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-2727.2016.04.007&rft.externalDocID=668482373 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93752X%2F93752X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |